Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient "Celecoxib" has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, as confirmed via the CDE's public registration information platform.

Celecoxib is primarily indicated for relieving the signs and symptoms of osteoarthritis, adult rheumatoid arthritis, and ankylosing spondylitis, as well as for treating acute pain in adults.

The approval of the Celecoxib API signifies that the product meets China's relevant technical standards for drug evaluation and is cleared for use in domestically marketed pharmaceutical preparations.

This development is expected to aid the company in expanding the product's sales within the domestic market, fostering a favorable sales structure that operates concurrently in both domestic and international markets.